Lanthanum Viatris (Lanthanum)

Lanthanum binds phosphate ions within the gastrointestinal tract, forming insoluble lanthanum‑phosphate complexes that are not absorbed. These complexes are eliminated in the feces, decreasing the amount of phosphate entering the bloodstream and thereby helping to control serum phosphate levels in patients with impaired renal excretion.

The dose of Lanthanum Viatris is individualized by the prescribing clinician based on the patient’s serum phosphate measurements, dietary phosphate intake, and overall renal function. The prescriber adjusts the amount to achieve target phosphate levels while minimizing side effects.

Safety data for lanthanum during pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians typically evaluate each case carefully and may consider alternative therapies when possible.

To order Lanthanum Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lanthanum Viatris is an oral, non‑calcium phosphate binder, which can be advantageous for patients at risk of hypercalcemia. Compared with calcium‑based binders, it does not add calcium load, and unlike sevelamer, it does not contain a high amount of polymeric material. Choice of binder depends on individual patient needs, tolerability, and cost considerations.

Lanthanum Viatris should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and light. Do not store in a refrigerator or freezer unless the label specifically indicates otherwise.

Lanthanum Viatris is taken orally, usually with meals to maximize phosphate binding. The tablet or powder is swallowed with a sufficient amount of water, and dosing times should be spaced at least two hours apart from other oral medications that may interact with its absorption.

Serious risks include severe constipation or bowel obstruction, which may require medical intervention, and rare allergic reactions that can manifest as rash, swelling, or anaphylaxis. In uncommon cases, lanthanum may contribute to hypercalcemia or liver enzyme abnormalities, so monitoring is advised.

Lanthanum Viatris should be avoided in patients with known hypersensitivity to lanthanum or any component of the formulation, those with active gastrointestinal obstruction, and individuals for whom phosphate binding is contraindicated. Caution is also advised for patients with severe liver disease or those who are pregnant or breastfeeding unless clearly indicated by a physician.